Company news: Forest Labs

Share this article:
FDA approved Forest's Daliresp (roflumilast) for the treatment of severe chronic COPD in adults 18 and up. The daily pill is indicated for decreasing the frequency of flare-ups or worsening of symptoms including breathlessness, chronic cough and excessive phlegm associated with bronchitis. The first-in-class drug is not indicated for treatment of primary emphysema, another form of COPD.
Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.